- Asahi Kasei Life Science acquired license rights from The Noguchi Institute for a novel ADC technology.
- Technology provides precise control of drug-to-antibody ratio (DAR) and attachment site for single- and dual-payload ADCs.
- Modality enables conjugation of two different payloads on a single antibody, expanding targeting scope and aiming to reduce off-target toxicity.
- Partners plan commercialization, possible sublicensing to biopharma and CDMOs (e.g., Bionova Scientific), and joint research to further refine the platform.
Transaction
Asahi Kasei Life Science acquired license rights from The Noguchi Institute for a novel antibody-drug conjugate (ADC) technology that enables precise control of drug-to-antibody ratio (DAR) and attachment site for single- and dual-payload ADCs.
Technology
Building on Noguchi’s carbohydrate and glycan research, the modality produces superior molecular structure conformity, which is expected to improve predictability of efficacy and safety and deliver more stable therapeutic effects; it also permits conjugation of two different payloads on a single antibody, expanding targeting options and potentially reducing off-target toxicity.
Next steps
The partners will advance commercialization of ADC platforms, consider sublicensing to biopharma companies and CDMOs (including Bionova Scientific), and undertake joint research to further refine the technology for medical applications.
